News Article | February 22, 2017
SMis Paediatric Clinical Trials show returns to London for the 11th year on 20th-21st March 2017. London, United Kingdom, February 22, 2017 --( Through a series of interactive conference sessions, presentations and a workshop led by industry experts; the 2017 agenda will discuss current clinical trials, implementation, drug development, recruitment and retention, ethical issues and regulations. Key presentations not to be missed: - Bianca McDade, Director Regulatory Affairs, GSK - Tom Willgoss, Senior Outcomes Research Scientist, Patient-Centred Outcomes Research, Roche - Karl-Heinz Huemer, Scientific Committee Member and Expert, EMA, PDCO - Hernando Patino, Paediatric Drug Development Lead, Johnson & Johnson - Deborah Lee, VP Clinical Development, Insys Therapeutics - Andy Kenwright, Senior Statistical Scientist, Roche - Robert Kahn, Former Senior Safety Science Leader, Global Pediatric Oncology, Genentech Highlights for 2017: - Update from the EMA on the PDCO's 10 year review into paediatric investigation plans - Discuss clinical trial legislation in the EU and US - Review challenges in paediatric drug development for rare diseases - Optimise approaches to paediatric drug formulation to improve clinical success - Evaluate recruitment and retention - Discuss hot topic of data extrapolation In the lead up to the event SMi have released some pre-conference interviews with some of the speakers. For further insight into the topics being discussed at this year’s conference and an overall look into the paediatric trials field visit the download centre of the event website to access the 2017 speaker interview series. Interviews available to download include: Roche, Insys Therapeutics, Paediatric Research Consultancy, The Birmingham Children’s Hospital and Klausrose Consulting. Countries attending Paediatric Clinical Trials 2017 include: Australia, Austria, Belgium, Denmark, France, Germany, Netherlands, Spain, Switzerland, United Kingdom & USA. For those who are interested in attending register online at the event website www.paediatric-trials.co.uk/prcom Paediatric Clinical Trials 20-21 March 2017 Copthorne Tara Hotel, London, UK www.paediatric-trials.co.uk/prcom Sponsorship enquiries: Contact Alia Malick on: +44 (0) 20 7827 6168 or email email@example.com Group bookings: Contact Ameenah Begum on: +44 (0) 20 7827 6166 or email firstname.lastname@example.org About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk London, United Kingdom, February 22, 2017 --( PR.com )-- With just 4 weeks to go, registration will be closing soon for SMi’s Paediatric Clinical Trials 2017. The event will bring together Clinical Operations Leads and Heads of Clinical Trials to review the developments leading to the advancement of paediatric medicines.Through a series of interactive conference sessions, presentations and a workshop led by industry experts; the 2017 agenda will discuss current clinical trials, implementation, drug development, recruitment and retention, ethical issues and regulations.Key presentations not to be missed:- Bianca McDade, Director Regulatory Affairs, GSK- Tom Willgoss, Senior Outcomes Research Scientist, Patient-Centred Outcomes Research, Roche- Karl-Heinz Huemer, Scientific Committee Member and Expert, EMA, PDCO- Hernando Patino, Paediatric Drug Development Lead, Johnson & Johnson- Deborah Lee, VP Clinical Development, Insys Therapeutics- Andy Kenwright, Senior Statistical Scientist, Roche- Robert Kahn, Former Senior Safety Science Leader, Global Pediatric Oncology, GenentechHighlights for 2017:- Update from the EMA on the PDCO's 10 year review into paediatric investigation plans- Discuss clinical trial legislation in the EU and US- Review challenges in paediatric drug development for rare diseases- Optimise approaches to paediatric drug formulation to improve clinical success- Evaluate recruitment and retention- Discuss hot topic of data extrapolationIn the lead up to the event SMi have released some pre-conference interviews with some of the speakers. For further insight into the topics being discussed at this year’s conference and an overall look into the paediatric trials field visit the download centre of the event website to access the 2017 speaker interview series. Interviews available to download include: Roche, Insys Therapeutics, Paediatric Research Consultancy, The Birmingham Children’s Hospital and Klausrose Consulting.Countries attending Paediatric Clinical Trials 2017 include: Australia, Austria, Belgium, Denmark, France, Germany, Netherlands, Spain, Switzerland, United Kingdom & USA. For those who are interested in attending register online at the event website www.paediatric-trials.co.uk/prcomPaediatric Clinical Trials20-21 March 2017Copthorne Tara Hotel, London, UKwww.paediatric-trials.co.uk/prcomSponsorship enquiries: Contact Alia Malick on: +44 (0) 20 7827 6168 or email email@example.comGroup bookings: Contact Ameenah Begum on: +44 (0) 20 7827 6166 or email firstname.lastname@example.orgAbout SMi Group:Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk Click here to view the list of recent Press Releases from SMi Group
News Article | February 16, 2017
While the medicinal cannabis industry continues to rapidly advance and expand operations by identifying new leading edge products, leaders are turning towards the expertise and knowledge of other medical sectors, especially with influence from the biopharma sector. Medical Marijuana and legal cannabis companies in the markets with recent developments and performance of note include: INSYS Therapeutics, Inc. (NASDAQ: INSY), Vinergy Resources Ltd (OTC: VNNYF) (CSE: VIN.CN), Canopy Growth Corporation (OTC: TWMJF) (TSX: WEED.TO), Aurora Cannabis Inc. (OTC: ACBFF) (TSX-V: ACB.V), Aphria Inc. (OTC: APHQF) (TSX-V: APH.V). Vinergy Resources Ltd (OTCQB: VNNYF) (CSE:VIN), in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop a lab for research and development products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, it has appointed John Simon to the Company's Scientific Advisory Board (SAB). John has a Bachelor of Science from the University of Alberta, is a senior member of the American Society for Quality, a Certified Quality Auditor (CQA), a Registered Quality Assurance Professional in Good Laboratory Practice (RQAP-GLP) and maintains Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society. Read this and more news for Vinergy Resources at: http://marketnewsupdates.com/news/vnnyf.html Through John's consultancy practice, he assists companies with both site licenses and product licenses. He has helped companies obtain, renew and maintain in good standing Drug Establishment Licenses (DEL); Medical Device Establishment Licenses (MDEL); Natural and Non-prescription Site Licenses (NNHPD); and Licenses to Cultivate and Distribute under the Marihuana for Medical Purposes Regulations (MMPR) (now under the ACMPR). "With John's substantial background in QA and regulatory affairs specific to drug development and the cannabis industry, he will be a key asset in driving our cannabis product and technology initiatives," said Mr.Kent Deuters, CEO of MJ Biopharma. Vinergy Resources also announced this week a major breakthrough while conducting research and development on oral cannabinoid complex (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN) and Terpenes) delivery strips and controlled time release capsule technology. This novel approach will be the basis for several products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body. In other cannabis - legal marijuana market performances and developments of note include: Aurora Cannabis Inc. (OTCQB: ACBFF) (TSX-V: ACB.V) a dually-listed company on Wednesday closed up on the OTC markets at $1.96 trading over 500,000 shares and closed even on the TSX at $2.56 trading over 2.6 million shares by the market close. Aurora Cannabis and Radient Technologies (RTI.V) this week provided an update on their previously announced collaboration arrangements. Read the full announcement at http://finance.yahoo.com/news/aurora-cannabis-radient-technologies-exclusive-124000123.html Canopy Growth Corporation (OTC: TWMJF)(TSX: WEED.TO) this week released its financial results for the third quarter of fiscal year 2017, the period ended December 31 , 2016. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Consolidated financial results include the accounts of the Company and its wholly-owned subsidiaries which include Tweed Inc. ("Tweed"), Tweed Farms Inc. ("Tweed Farms"), and Bedrocan Canada Inc. ("Bedrocan Canada") and its investments in affiliates. Read the full report at http://finance.yahoo.com/news/canopy-growth-corporation-reports-third-113000287.html Aphria Inc. (OTCQB: APHQF) (TSX-V: APH.V) a dually listed company on Wednesday closed up on the OTC markets at $5.01 trading over 400,000 shares and closed up on the TSX at $6.52 trading over 4.8 million shares by the market close. Aphria, one of Canada's lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. INSYS Therapeutics, Inc. (NASDAQ: INSY) closed up over 12% on Wednesday at $10.82 trading over 3.2 Million shares by the market close. Insys Therapeutics this week announced that the Company is providing for the use of Cannabidiol Oral Solution at doses up to 40 mg/kg/day in compassionate use studies in subjects with refractory pediatric epilepsy following completion of 48 weeks of treatment in the ongoing long-term safety study. The long-term safety study permitted subjects who had completed the initial safety and pharmacokinetic (PK) study to receive Cannabidiol Oral Solution at doses up to 40 mg/kg/day for up to 48 weeks. DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Vinergy Resources Ltd by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
News Article | March 1, 2017
Research and Markets has announced the addition of the "Aortic Aneurysm Repair Devices Global Market - Forecast to 2023" report to their offering. The Aortic Aneurysm Repair Devices market is classified based on site, product, repair type and geography. The Aortic Aneurysm Repair Devices products market is divided into Stent grafts, Catheters, and Others. The Aortic Aneurysm Repair Devices by site market is segmented into Abdominal Aortic Aneurysm (AAA) and Thoracic Aortic Aneurysm (TAA). Abdominal aortic aneurysm market is further segmented into Infrarenal and Perarenal. The perarenal market is further sub-segmented into Juxtrarenal and Suprarenal. Thoracic Aortic Aneurysm market is divided into Ascending an aortic aneurysm, Descending aortic aneurysm, Thoracoabdominal Aortic Aneurysm (TAAA) and Thoracic Arch Aneurysm. The Aortic Aneurysm market by repair type is divided into Abdominal Aortic Aneurysm (AAA) and Thoracic Aortic Aneurysm (TAA). Abdominal aortic aneurysm is divided into open surgery and Endovascular aneurysm repair (EVAR). Thoracic aortic aneurysm repair is divided into open surgery and Thoracic endovascular aneurysm repair (TEVAR). Further, the Aortic Aneurysm Repair Devices market is separated by geographical regions into North America, Europe, Asia-pacific and Rest of the World. 2 Introduction 2.1 Key Take Aways 2.2 Report Description 2.3 Markets Covered 2.4 Stakeholders 2.5 Research Methodology 2.5.1 Market Size Estimation 2.5.2 Market Crackdown and Data Triangulation 2.5.3 Secondary Sources 2.5.4 Primary Sources 2.5.5 Key Data Points from Secondary Sources 2.5.6 Key Data Points from Primary Sources 2.5.7 Assumptions 3 Market Analysis 3.1 Introduction 3.2 Market Segmentation 3.3 Factors Influencing Market 3.3.1 Drivers and Opportunities 22.214.171.124 Rising Geriatric Population 126.96.36.199 Increasing Prevalence of Lifestyle Diseases 188.8.131.52 Growing Acceptance for Minimally Invasive Endovascular Surgeries 184.108.40.206 Technological Advancements in Evar 220.127.116.11 Mergers and Acquisitions 18.104.22.168 Market Expansion Opportunities in Emerging Nations 3.3.2 Restraints and Threats 22.214.171.124 Risks Associated With Endovascular Procedures Such as Endoleaks and Radiation Exposure 126.96.36.199 High Costs of an Endovascular Aneurysm Repair Procedures 188.8.131.52 Stringent Regulatory Approval Requirement for an Aortic Aneurysm Repair Product 184.108.40.206 Lack of Skilled Professionals 220.127.116.11 Challenges Associated With Repair of Complex Anatomies 18.104.22.168 Off-The-Shelf Stent Grafts in Treating Complex Anatomies 3.4 Regulatory Affairs 3.4.1 U.S. 3.4.2 Europe 3.4.3 India 3.4.4 China 3.4.5 Japan 3.5 Reimbursement Scenario 3.5.1 Reimbursement Table 3.6 Porter's Five Force Analysis 3.6.1 Threat of New Entrants 3.6.2 Threat of Substitutes 3.6.3 Bargaining Power of Suppliers 3.6.4 Bargaining Power of Buyers 3.6.5 Competitive Rivalry 3.7 Market Share Analysis 3.7.1 Aortic Aneurysm Repair Devices Global Market Share Analysis, by Major Players 3.7.2 Evar Global Market Share Analysis, by Major Players 3.7.3 Tevar Global Market Share Analysis, by Major Players 3.7.4 U.S. Evar Market Share Analysis, by Major Players 3.7.5 Europe Evar Market Share Analysis, by Major Players 3.7.6 Japan Evar Market Share Analysis, by Major Players 3.8 Patent Trends 8 Company Developments 8.1 Introduction 8.1.1 Product Approval as a Major Growth Strategy of Market Players 8.2 Product Approval 8.3 Agreements and Acquisitions 8.4 New Product Launch 8.5 Other Developments - Abiomed (U.S.) - B.Braun GmbH (Germany) - BiFlow medical (Israel) - Bolton Medical (U.S.) - Boston Scientific corporation (U.S.) - Braile Biomedica (Brazil) - Cardiatis (Belgium) - Cardinal Health, Inc. (U.S.) - Cook Medical, Inc. (U.S.) - Cytograft Tissue Engineering, Inc. (U.S.) - Endologix, Inc. (U.S.) - Endospan (Israel) - Fuji Systems Corporation (Japan) - Getinge Groups (Maquet) (Sweden) - GRIKIN Advanced Materials (China) - HDH Medical Ltd (Israel) - JOTEC GmbH (Germany) - Le Maitre Vascular, Inc. (U.S.) - LifeTech Scientific Corporation (China) - Lombard Medical Technologies (U.K.) - Medtronic PLC (Ireland) - MicroPort Scientific Corporation China) - Nano Endoluminal S.A. (Brazil) - S & G Biotech, Inc. (South Korea) - St. George Medical (France) - Terumo Medical Corporation (Japan) - Transcatheter Technologies GmbH (Germany) - Vivasure Medical (Ireland) - W. L. Gore and Associates (U.S.) For more information about this report visit http://www.researchandmarkets.com/research/4tpcxn/aortic_aneurysm Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
News Article | March 1, 2017
LOUISVILLE, Ky., March 01, 2017 (GLOBE NEWSWIRE) -- Churchill Downs Incorporated (NASDAQ:CHDN) (“CDI”) today announced that it has promoted Brad Blackwell to Senior Vice President and General Counsel. The promotion is effective immediately. Blackwell joined CDI in 2005 and has held numerous roles of increasing responsibility, including Corporate Counsel (2005-2007); Vice President, Legal & Regulatory Affairs for TwinSpires (2007-2011); Vice President, Legal for CDI (2011-2015); and Vice President, Operations for CDI (2015-2017). Prior to joining CDI, Blackwell was Assistant General Counsel and Secretary for Michaels Stores, Inc. in Irving, Tx., and an Associate Attorney in the Dallas office of Jones Day. Blackwell is a 1994 graduate of the University of Kentucky with a B.S. in Accounting. He received his J.D. from the Brandeis School of Law at the University of Louisville in 1998. “Brad is an exceptional attorney who has been pivotal to the success of our company,” CDI Chief Executive Officer Bill Carstanjen said. “I have worked with Brad for twelve years and I know that his legal and business experience combined with his deep knowledge of our company will serve him well as our General Counsel.” “I look forward to leading our outstanding legal team and working closely with our numerous businesses to continue the growth of CDI,” said Blackwell. ABOUT CHURCHILL DOWNS INCORPORATED Churchill Downs Incorporated, (CDI) (NASDAQ:CHDN), headquartered in Louisville, Ky., is an industry-leading racing, gaming and online entertainment company anchored by our iconic flagship event - The Kentucky Derby. We are a leader in brick-and-mortar casino gaming with gaming positions in eight states, and we are the largest legal online account wagering platform for horseracing in the U.S., through our ownership of TwinSpires.com. We are also one of the world’s largest producers and distributors of mobile games through Big Fish Games, Inc. Additional information about CDI can be found online at www.churchilldownsincorporated.com.
News Article | February 15, 2017
OTTAWA, ONTARIO--(Marketwired - Feb. 9, 2017) - Tetra Bio-Pharma Inc. ("Tetra") (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) and IntelGenx Corp. ("IntelGenx"), (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the binding term sheet, Tetra will have exclusive rights to sell the product in North America with a right of first negotiation for outside the U.S. and Canada. The U.S. cancer pain market is expected to reach $5 billion in 2018. Per the Binding Term Sheet, Tetra will make a non-refundable exclusive negotiation payment to IntelGenx, an upfront payment along with set milestone payments based on the completion of an efficacy study, approvals from FDA and Health Canada and launching of the product. IntelGenx will be responsible for the research and development of the product, including clinical studies and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa® controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals, including the application and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the drug product. "We are pleased to partner with Tetra Bio-Pharma to enter the lucrative cannabis market," said Dr. Horst G. Zerbe, President and CEO of IntelGenx. "We will work with Tetra to bring this much needed THC product to North American patients suffering from anorexia and cancer chemotherapy-related pain. This announcement is a further testament to the strength of IntelGenx' scientists who continue to execute the development of innovative products using our advanced oral delivery platforms." PhytoPain Pharma Inc., a subsidiary of Tetra will be submitting a request for a Type B pre-IND meeting with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP), Center for Drug Evaluation and Research (CDER), USA Food and Drug Administration (FDA) to discuss the marketing requirements for Dronabinol AdVersa® Mucoadhesive tablet product. Tetra intends on developing Dronabinol AdVersa® Mucoadhesive tablet as an analgesic for the management of Breakthrough Cancer Pain. Once the safety and efficacy is demonstrated in patients, this drug product will be eligible for approval under the 505(b)(2) New Drug Application (NDA) path commented Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs. The 505(b)(2) pathway represents a significant reduction in time and cost to market commented Dr. Chamberland. He added that the company will also be meeting with the Therapeutic Product Directorate, Health Canada to discuss the clinical development and marketing requirements. Dr. Chamberland further commented that there are many clinical problems associated with the use of currently available form of Dronabinol in patients with anorexia and cancer chemotherapy. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of THC and its metabolite significantly affect the abuse potential of Dronabinol. The significant advantage of the Mucoadhesive technology is the controlled-release of THC resulting in a longer time release of the drug avoiding a rapid increase in the blood. There is also an improved bioavailability and potentially reduced gastro-intestinal side effects making the sustained-release THC product a promising alternative in the battle for the reduction of opioids in patients with chronic pain. IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX. IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilmTM technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com. Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements. Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com. The Canadian Securities Exchange ("CSE") has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
News Article | March 2, 2017
On Wednesday, Canada's federal telecom regulator ordered a small, affordable competitor in the country's oligarchic mobile market to shut down. Sugar Mobile is an Ontario-based provider owned by Ice Wireless, a company that also owns a wireless network in the North. For just $19 per month—an exceedingly low price for a mobile plan in Canada—Sugar Mobile allowed customers to call and send texts over WiFi, only using Ice Wireless' network when WiFi was unavailable. It's very similar to how Google's Project Fi works in the US. Like Project Fi, Sugar Mobile is what's known as an "mobile virtual network operator," or MVNO. This means that although Sugar Mobile doesn't own any of its own infrastructure, it piggybacks off of the network of a larger provider—in this case, its parent company. Because of a roaming agreement between Ice Wireless and Rogers, one of Canada's "big three" telecom companies, Sugar Mobile also used Rogers as its network when both WiFi and Ice Wireless weren't available. This was helpful for Ice Wireless' customers in the North, especially when travelling to cities where the provider doesn't have coverage. The order to shut down Sugar Mobile came about because Rogers complained that customers outside of the North would always be using Rogers' network, violating the roaming agreement. It's a big mess that could have been easily avoided if the Canadian Radio-television and Telecommunications Commission (CRTC) approved mandatory access for MVNOs. "It's like, welcome to Canada" In a landmark ruling in 2015, the CRTC effectively put the kibosh on MVNOs operating at scale in Canada by declining to mandate that large providers lease their networks to smaller competitors. The reasoning at the time was that mandating small companies to be able to buy network access would disincentivize building new wireless infrastructure. Some organizations pushed back, but their appeal was ultimately denied by the CRTC. While there's nothing stopping Canadian telecoms from approving MVNO services on their networks, without a rule making such access mandatory, they've so far elected to not play nice with competition. "[Being an MVNO] was part of the initial discussions, and Rogers was not open to entertaining that," said Sugar Mobile president Samer Bishay over the phone. "They said, 'We have these requests every day and we decline all of them.'" "It's like, welcome to Canada," Bishay continued. "In the US, you have 250 MVNOs. Of course this could have been avoided, but who's going to do it?" Rogers, when asked for comment on whether Sugar Mobile being an MVNO on the Rogers network was part of the initial negotiations, sent Motherboard an emailed statement from David Watt, Rogers' Senior Vice President of Regulatory Affairs, that did not directly respond to Bishay's allegations. Read More: Canada Has Some of the Most Expensive Data In the World, and That's Not OK "We're pleased the [Canadian Radio-television and Telecommunications Commission] made the right call," Watt said in the emailed statement. "We believe in innovation and a fair, competitive market—this was about violating a roaming agreement, plain and simple." Still, it's a familiar story. Consider the case of an MVNO based in Toronto: Ting. While Ting is rather successful in the US, working with Sprint and T-Mobile, it hasn't enjoyed the same generous reception from Canadian telecom giants. "Sprint and T-Mobile are our providers in the states—there's no legal requirement for them to offer service, but it makes sense for them to do that," said Andrew Moore-Crispin, Ting's head of content, in a phone interview. "Canadian carriers are disincentivized to invite competition in. We all know we're paying $80 for our single cell phone plans, so there's a disincentive to change that." Right now, small providers have precious few options in Canada, Crispin-Moore continued. "You either build your network from scratch, and you find a backdoor and see what happens," he said. Sugar Mobile arguably chose the latter option, and it didn't end well. As long as the Canadian mobile market is dominated by three companies, ordering that they share their networks with smaller competitors may be the only way to ensure that companies with similar ambitions don't get burned. Get six of our favorite Motherboard stories every day by signing up for our newsletter .
News Article | February 15, 2017
Charm Sciences, Inc. is pleased to announce the Charm TRIO test (TRIO) has received AOAC Performance Tested Methods (SM) (PTM) certification 121601. The Charm TRIO test detects beta-lactams, sulfonamide drugs, and tetracyclines in raw commingled milk at or below Canadian Maximum Residue Limits and US Tolerance/Target Levels in 3 minutes. “The TRIO test is the first multiplex assay validated by AOAC Research Institute (AOAC-RI) for three families of antibiotics,” said Bob Salter, Vice President of Regulatory Affairs for Charm Sciences. “The TRIO test is widely used in milk production, on farms, milk trucks, in dairy manufacturing, and in milk testing laboratories, due to speed, ease of use and broad detection ranges. Dairy stakeholders are increasingly interested in validating proper medicinal use in animal treatment and in assuring residue-free milk production beyond the most commonly used beta-lactam antibiotics. This validates a tool that casts a wider net in milk quality and production control that reduces time and complexity.” The Charm TRIO test is a lateral flow strip that detects three antibiotic families. It uses patented technology to target drug sensitivities at regulatory levels, which prevents unnecessary rejection of milk caused by overly sensitive screening tests. Results may be obtained using the Charm EZ system, an incubator and reader in one compact unit. Data can be transferred via Ethernet connection to network systems for full traceability with auto-alerts when positive loads are detected. About Charm Sciences, Inc. Charm Sciences is a world leader provider of food safety, water quality and environmental diagnostics. Charm’s diagnostics portfolio includes test kits and systems for antibiotics, mycotoxins, pesticides, alkaline phosphatase, microorganisms, end product microbial assessment, allergen control, water quality and ATP hygiene. Directly and through its network of distributors, Charm products serve the food, beverage, water, pharmaceutical, medical, personal care, environmental, and industrial markets in more than 100 countries. Customers rely on Charm products for excellence in quality, innovation and customer support. About AOAC-RI This method’s performance was reviewed by AOAC Research Institute and was found to perform to the manufacturer’s specifications. The AOAC Research Institute (AOAC-RI) was incorporated in 1991 as a wholly owned subsidiary of AOAC INTERNATIONAL. The AOAC-RI serves as an independent, third-party, nongovernment administrator of AOAC conformity assessment programs including the AOAC Performance Tested Methods(SM) (PTM) and Official Methods of Analysis(SM) (OMA) programs for alternative and sole source methods. For more information, visit http://www.aoac.org.
News Article | February 28, 2017
The American wind energy industry is confident in the ability of current and future conservation measures to protect the hoary bat species from being threatened by wind turbines. The American Wind Energy Association responded this week to a recently published study which raised the spectre of extinction for Lasiurus cinereus, the hoary bat. According to the study, published in the journal Biological Conservation and authored by a group of international experts, concluded that 128,000 hoary bats are killed each year (though the available press material and journal abstract do not explicitly state this figure is entirely the fault of wind turbines), and that even if no new wind turbines are built over the next 50 years, the species’ population could decline by as much as 90% over the same period. “The hoary bat could be the next spotted owl,” said Mike Daulton, Executive Director of Bat Conservation International. “This species is headed for the emergency room if we don’t act now.” “These findings are a wakeup call. Our study focused on the hoary bat, which has the highest observed fatalities,” explained Winifred Frick, Senior Director of Conservation Science for Bat Conservation International and lead author on the paper. “Other migratory bats also have high levels of mortality from wind turbines.” “We need to implement significant conservation measures to reduce mortality from wind turbine collisions and soon — effective conservation measures will help not just hoary bats but all bats that get killed by turbines.” Over the past several decades there have always been studies investigating the impact wind turbines have on the mortality of wildlife — and in almost every situation I can pinpoint, wind energy developers are not only required but enthusiastic about conducting serious and intensive wildlife conservation research and studies on their prospective sites. Additionally, as explained by the American Wind Energy Association (AWEA) in its response to the new research, the studies’ conclusions do not necessarily take into account all the relevant facts. “The wind industry is confident that the conservation measures we have put in place and those in the pipeline can prevent the scenario articulated in this study,” said Tom Vinson, Vice President of Federal Regulatory Affairs with the AWEA. “These conservation measures were not considered by the authors.” “The wind energy industry takes its wildlife conservation responsibilities seriously, including with respect to bats, and is proactively working to reduce our impacts. Even for bats that are not protected by federal law, the industry conducts pre-construction studies to understand potential risks and develops bat conservation strategies to address any concerns. That includes provisions to implement additional conservation measures if issues arise, and monitoring at operating facilities to verify actual impacts.” The Bat Conservation International experts report were similarly not as doom-and-gloom as the report detailed. “Solutions are within our grasp,” said Mike Daulton. “We have great hope that this is a problem that the conservation community, key government agencies and the wind industry can work together to solve.” The AWEA also commented on some of these “solutions” that might help mitigate undue harm to bat populations. “Early results of the research into acoustic deterrent devices, for example using ultrasonic sounds that bats can detect to ward them away from turbines, have shown promise and that research continues,” explained Tom Vinson. “Various bat species have been significantly harmed by white nose syndrome and are at further risk as a result of climate change, for which expanding wind energy is a leading solution. The wind industry has a legacy of care for the environment and will continue to work to protect bats while addressing these larger threats to their survival.” Buy a cool T-shirt or mug in the CleanTechnica store! Keep up to date with all the hottest cleantech news by subscribing to our (free) cleantech daily newsletter or weekly newsletter, or keep an eye on sector-specific news by getting our (also free) solar energy newsletter, electric vehicle newsletter, or wind energy newsletter.
News Article | February 16, 2017
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 16, 2017) - Vinergy Resources Ltd. ("Vinergy" or the "Company") (CSE:VIN)(OTCQB:VNNYF) in conjunction with its proposed acquisition of MJ BioPharma (announced December 14, 2016) is pleased to announce that, as a part of the Company's strategy to develop a lab for research and development products that test and identify specific cannabinoid isolates for targeted therapeutic purposes, it has appointed John Simon to the Company's Scientific Advisory Board (SAB). John has a Bachelor of Science from the University of Alberta, is a senior member of the American Society for Quality, a Certified Quality Auditor (CQA), a Registered Quality Assurance Professional in Good Laboratory Practice (RQAP-GLP) and maintains Regulatory Affairs Certification (RAC) through the Regulatory Affairs Professional Society. John has held various management positions in Quality Assurance and Regulatory Affairs and has worked as a consultant supporting clients in the medical device, pharmaceutical, biotechnology and natural health product industries since 2004. He has been directly involved in Federal Drug Administration (FDA) and Health Canada audits of medical device manufacturers, drug manufacturers, testing facilities, and clinical sites. He has experience with submissions to the FDA and Health Canada. Through John's consultancy practice he assists companies with both site licenses and product licenses. He has helped companies obtain, renew and maintain in good standing Drug Establishment Licenses (DEL); Medical Device Establishment Licenses (MDEL); Natural and Non-prescription Site Licenses (NNHPD); and Licenses to Cultivate and Distribute under the Marihuana for Medical Purposes Regulations (MMPR) (now under the ACMPR). John also works in creating quality systems to support ISO certification for various clients (ISO 17025, ISO 13485 and ISO 9001). John consults to groups in the creation of specifications, batch records and procedures to support the design and development of a variety of products including cosmetics, natural health products, medical devices, biologics, pharmaceuticals and controlled substances. "With John's substantial background in QA and regulatory affairs specific to drug development and the cannabis industry he will be a key asset in driving our cannabis product and technology initiatives," said Mr.Kent Deuters, CEO of MJ Biopharma. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. The CSE does not accept responsibility for the adequacy or accuracy of this release. The forward-looking information contained in this press release is made as of the date of this press release and, except as required by applicable law, the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking information, whether as a result of new information, future events or otherwise, except as may be required by law. By its very nature, such forward-looking information requires the Company to make assumptions that may not materialize or that may not be accurate. This forward-looking information is subject to known and unknown risks and uncertainties and other factors, which may cause actual results, levels of activity and achievements to differ materially from those expressed or implied by such information. Information pertaining to the Target has been provided by the Target.
News Article | March 1, 2017
NKT Cables’ projektforretning, som består af AC/DC on- og offshore højspændingskabler vil blive ledet af Andreas Berthou, tidligere direktør for ABB HV Cables. Andreas Berthou har arbejdet for selskabet siden 1999 og har omfattende erfaring i branchen for AC/DC on- og offshore højspændingskabler. Detlev Waimann, som tidligere har ledet NKT Cables’ projektforretning, bliver Chief Technology Officer (CTO) med ansvar for bl.a. selskabets omfattende R&D- og innovationsaktiviteter samt Regulatory Affairs. NKT Cables CEO Michael Hedegaard Lyng siger: - Vi er godt forberedt til integrationen af NKT Cables og ABB HV Cables, og sammen vil vi bringe selskabet til et nyt niveau. Den samlede forretning vil have en ledende og aktiv rolle i den globale energitransformation og vi kan tilbyde vores kunder innovative løsninger, som er teknologisk førende i industrien. Desuden glæder vi os til at byde alle medarbejdere i ABB HV Cables velkommen på den spændende rejse, der starter i dag.